|Videos|November 4, 2022
Data on Real-World Use of Belantamab Mafodotin in R/R MM
Dr Shonali Midha continues her analysis of belantamab mafodotin with a look at data on real-world use in R/R MM since its FDA approval in August 2020.
Advertisement
Episodes in this series
Advertisement
Related to this article
Natalie S. Callander, MD, discussed the rationale for combining selinexor, carfilzomib, subcutaneous isatuximab, and dexamethasone in relapsed/refractory myeloma.
C. Ola Landgren, MD, PhD, discusses the FDA’s endorsement of MRD as an accelerated approval end point in multiple myeloma.
Hans C. Lee, MD, discussed how community oncologists with limited access to MRD testing can think about the new IMS/IMWG definition of cure in myeloma.
Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
Expanding CAR T and Bispecific Antibody Research in HIV-Associated Lymphoma
2
Rinatabart Sesutecan Elicits Responses in PROC Regardless of FRα Expression
3
Why High-Risk Stage I NSCLC Needs a Post-Surgical Vaccine Option
4
How Emory Became the First Adopter of the Liberty Endovascular Robotic System
5